ALNEV.PA Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary ():

Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France...

Stats
Dagens volum	0
Gjennomsnittsvolum	0
Markedsverdi	0
EPS	0 ( 2019-10-02 )
Last Dividend	0 ( N/A )
Next Dividend	0 ( N/A )
P/E	0
ATR14	0 (0.00%)

Neovacs SA Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Neovacs SA Økonomi

Annual	2022
Omsetning:	1 112.00
Bruttogevinst:	-3.43M (-308 866.37 %)
EPS:	-117.60

FY	2022
Omsetning:	1 112.00
Bruttogevinst:	-3.43M (-308 866.37 %)
EPS:	-117.60

FY	2021
Omsetning:	22 595.00
Bruttogevinst:	-462 306 (-2 046.05 %)
EPS:	-7 841.13

FY	2020
Omsetning:	30 142.00
Bruttogevinst:	-89 853.00 (-298.10 %)
EPS:	-4 068.95

Financial Reports:

No articles found.

Neovacs SA

Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.